Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2004-07-13
2008-10-28
Rao, Deepak (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S252140, C514S275000, C544S122000, C544S295000, C544S323000
Reexamination Certificate
active
07442698
ABSTRACT:
The present invention relates to pyrimidine or pyridine carbamate compounds having the general Formula I:and pharmaceutically acceptable salts or derivatives thereof. Also included are methods of treatment of various diseases and conditions, including inflammation, inhibition of T cell activation and proliferation, arthritis, organ transplant, ischemic or reperfusion injury, myocardial infarction, stroke, multiple sclerosis, inflammatory bowel disease, Crohn's disease, lupus, hypersensitivity, type 1 diabetes, psoriasis, dermatitis, Hashimoto's thyroiditis, Sjogren's syndrome, autoimmune hyperthyroidism, Addison's disease, autoimmune diseases, glomerulonephritis, allergic diseases, asthma, hayfever, eczema, cancer, colon carcinoma, thymoma, just to name a few, in a mammal, the methods comprising administering a therapeutically-effective amount a compound of Formula I, or a salt or derivative form thereof, as described above.
REFERENCES:
patent: 3331845 (1967-07-01), Tomcufcik
patent: 0039051 (1985-07-01), None
patent: 0486948 (2000-10-01), None
patent: WO9749710 (1997-12-01), None
patent: WO98/41512 (1998-09-01), None
patent: WO03/004492 (2003-01-01), None
patent: WO 03/018021 (2003-03-01), None
patent: WO03/048133 (2003-06-01), None
patent: WO 2005/009443 (2005-02-01), None
Casanova et al., PubMed Abstract (Rev Neurol. 28(9):909-15) May 1999.
Kane, LP et al. “Signal Transduction by the TCR for Antigen,” Current Opinion in Immunol. 12: 242 (2000).
Bolen, JB, and Brugge, “Leukocyte protein Tyrosine Kinases:Potential Targets for Drug Discovery” JS Annu. Rev. Immunol. 15: 371 (1997).
Soriano, P. Cell, “Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice” 64: 693 (1991).
Anderson, SJ et al. “Involvement of the Protein Tyrosine Kinase p56lckin T Cell Signaling and Thymocyte Development” Adv. Immunol. 56: 151 (1994).
Goldman, FD et al. “Defective Expression of p56lck in an Infant with Severe Combined Immunodeficiency” J. Clin. Invest. 102: 421 (1998).
Manser et.al., “A non-receptor tyrosine kinase that inhibits the GTPase activity of p21cdc42” Nature 363(6427): 364-367, (1993).
Appleby, MW et al. “Defective T Cell Receptor Signaling in Mice Lacking the Thymic Isoform of p59fyn” Cell 70: 751 (1992).
Vicentini, L. et al. “Fgr Deficiency Results in Defective Eosinophil Recruitment to the Lung During Allergic Airway Inflammation” J. Immunol. 168: 6446 (2002).
Turner, H. and Kinet, J-P “Signalling through the high-affinity IgE receptor Fc epsilon RI” Nature 402: B24 (1999).
Abram, CL and Courtneidge, SA “Src Family Tyrosine Kinases and Growth Factor Signaling” Exp. Cell Res. 254: 1 (2000).
Paul, R. et al. “Src deficiency or blockade of Src activity in mice provides cerebral protection following stroke” Nature Medicine 7: 222 (2001).
Snow, RJ et al. “Discovery of 2-Phenylamino-imidazo[4,5-h]isoquinolin-9-ones: A New Class of Inhibitors of Lck Kinase” J. Med. Chem. 45: 3394 (2002).
Burchat, AF et al. “Design, synthesis and brief SAR of pyrazolo(3,4-d) and pyrrolo(2,3-d)pyrimidines as potent inhibitors of lck” et al. Bioorganic and Med. Chem. Letters 12: 1687 (2002).
Hanke, JH et al. “Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase Inhibitor” J. Biol. Chem. 271: 695 (1996).
Altmann, E et al. “7-Pyrrolidinyl- and 7-piperidinyl-5-aryl-pyrrolo(2,3-d)-pyrimidines: Potent inhibitors of the tyrosine kinase c-Src” Bioorganic and Med. Chem. Letters 11: 853 (2001).
Wang, YD et al. “Inhibitors of Src Tyrosine Kinase: The Preparation and Structure-Activity Relationship of 4-Anilino-3-cyanoquinolines and 4-Anilinoquinazoles” Bioorganic and Med. Chem. Letters 10: 2477 (2000).
Chen, P. et al. “Synthesis and SAR of novel imidazoquinoxaline-based Lck inhibitors: Improvement of cell potency” Bioorganic and Med. Chem. Letters 12: 3153 (2002).
Berge et al., J. Pharm. Sci. 66:1 (1977).
Bundgaard, H. et al. “A Novel Solution-Stable Water-Soluble Prodrug Type For Drugs Containing A Hydroxyl Or An Amino-Acidic Group” J. Med. Chem. 32(12): 2503 (1989).
Terashima, K. et al. “Studies on Antiulcer Agents.II. 1) Antiulcer Protperties of N-(1H-Tetrazol-5-yl)-2-anilino-5-pyrimidinecarboxamides Inhibiting Release of Histamine from Passively Sensitized Rat Peritoneal Mast Cells” Chem. Pharm. Bull. 43(6): 1042-1044 (1995).
Buchanan John L.
Elbaum Daniel
Martin Matthew W.
McGowan David C.
Novak Perry M.
Amgen Inc.
Rao Deepak
Reddy G. Prabhaker
LandOfFree
Substituted heterocyclic compounds and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted heterocyclic compounds and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted heterocyclic compounds and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3991658